X4 PHARMACEUTICALS INC (XFOR) Stock Overview
USA - NASDAQ:XFOR - US98420X2027 - Common Stock
XFOR Key Statistics, Chart & Performance
The current stock price of XFOR is 2.97 USD. In the past month the price decreased by -8.33%. In the past year, price decreased by -80.94%.
XFOR Latest News, Press Relases and Analysis
XFOR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.42 | 400.78B | ||
| AMGN | AMGEN INC | 13.56 | 159.25B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 146.23B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.12 | 104.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.06B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.47 | 60.33B | ||
| ARGX | ARGENX SE - ADR | 90.32 | 51.24B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.14 | 34.93B | ||
| INSM | INSMED INC | N/A | 34.49B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.26B | ||
| NTRA | NATERA INC | N/A | 24.78B | ||
| BIIB | BIOGEN INC | 8.89 | 20.86B |
Related stock screener links
About XFOR
Company Profile
X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The company is headquartered in Boston, Massachusetts and currently employs 143 full-time employees. The company went IPO on 2017-11-16. The firm is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. The company has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). The company has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Company Info
X4 PHARMACEUTICALS INC
61 North Beacon Street, 4th Floor
Boston MASSACHUSETTS 02134 US
CEO: Paula Ragan
Employees: 143
Phone: 18575298300
X4 PHARMACEUTICALS INC / XFOR FAQ
What is the stock price of X4 PHARMACEUTICALS INC today?
The current stock price of XFOR is 2.97 USD. The price increased by 3.85% in the last trading session.
What is the ticker symbol for X4 PHARMACEUTICALS INC stock?
The exchange symbol of X4 PHARMACEUTICALS INC is XFOR and it is listed on the Nasdaq exchange.
On which exchange is XFOR stock listed?
XFOR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for X4 PHARMACEUTICALS INC stock?
11 analysts have analysed XFOR and the average price target is 8.87 USD. This implies a price increase of 198.79% is expected in the next year compared to the current price of 2.97. Check the X4 PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is X4 PHARMACEUTICALS INC worth?
X4 PHARMACEUTICALS INC (XFOR) has a market capitalization of 33.89M USD. This makes XFOR a Nano Cap stock.
How many employees does X4 PHARMACEUTICALS INC have?
X4 PHARMACEUTICALS INC (XFOR) currently has 143 employees.
What are the support and resistance levels for X4 PHARMACEUTICALS INC (XFOR) stock?
X4 PHARMACEUTICALS INC (XFOR) has a support level at 2.85 and a resistance level at 3.18. Check the full technical report for a detailed analysis of XFOR support and resistance levels.
Is X4 PHARMACEUTICALS INC (XFOR) expected to grow?
The Revenue of X4 PHARMACEUTICALS INC (XFOR) is expected to grow by 1511.73% in the next year. Check the estimates tab for more information on the XFOR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy X4 PHARMACEUTICALS INC (XFOR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of XFOR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of XFOR, evaluating the profitability, health, valuation and growth aspects
- X4 PHARMACEUTICALS INC (XFOR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- X4 PHARMACEUTICALS INC (XFOR) Sales and EPS estimates to see what analysts future expectations are.
- X4 PHARMACEUTICALS INC (XFOR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- X4 PHARMACEUTICALS INC (XFOR) Insider and Institutional Ownership to learn about the owners and their transactions.
- X4 PHARMACEUTICALS INC (XFOR) Stock Chart to make your own analysis
- X4 PHARMACEUTICALS INC (XFOR) Latest news and press-releases to stay up to date.
Does X4 PHARMACEUTICALS INC (XFOR) stock pay dividends?
XFOR does not pay a dividend.
When does X4 PHARMACEUTICALS INC (XFOR) report earnings?
X4 PHARMACEUTICALS INC (XFOR) will report earnings on 2025-11-11, before the market open.
What is the Price/Earnings (PE) ratio of X4 PHARMACEUTICALS INC (XFOR)?
X4 PHARMACEUTICALS INC (XFOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-14.83).
What is the Short Interest ratio of X4 PHARMACEUTICALS INC (XFOR) stock?
The outstanding short interest for X4 PHARMACEUTICALS INC (XFOR) is 18.18% of its float. Check the ownership tab for more information on the XFOR short interest.
XFOR Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to XFOR. When comparing the yearly performance of all stocks, XFOR is one of the better performing stocks in the market, outperforming 76.29% of all stocks.
XFOR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XFOR. XFOR may be in some trouble as it scores bad on both profitability and health.
XFOR Financial Highlights
Over the last trailing twelve months XFOR reported a non-GAAP Earnings per Share(EPS) of -14.83. The EPS decreased by -12.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -96.96% | ||
| ROE | -2568.02% | ||
| Debt/Equity | 19.1 |
XFOR Forecast & Estimates
11 analysts have analysed XFOR and the average price target is 8.87 USD. This implies a price increase of 198.79% is expected in the next year compared to the current price of 2.97.
For the next year, analysts expect an EPS growth of 82.32% and a revenue growth 1511.73% for XFOR